Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HCWB | EFFECT | neutral | 5/10 | HCW Biologics' S-1 registration (File No. 333-296577) became effective on June 18, 2026, enabling selling stockholders t | Jun 22, 2026 |
| LTRN | EFFECT | bearish | 6/10 | The SEC declared Lantern Pharma's S-1 registration statement effective on June 18, 2026, enabling selling stockholders t | Jun 22, 2026 |
| SLXN | EFFECT | neutral | 3/10 | Silexion Therapeutics Corp's S-3 shelf registration (File No. 333-296739) became effective on June 18, 2026. This allows | Jun 22, 2026 |
| CMND | EFFECT | bearish | 4/10 | Clearmind Medicine Inc.'s shelf registration statement (File No. 333-291817) became effective on June 18, 2026, allowing | Jun 22, 2026 |
| CRVO | 8-K | bearish | 7/10 | CervoMed priced a $10M registered direct offering of 2.5M shares at $4.00/share (at-the-market under Nasdaq rules), expe | Jun 22, 2026 |
| MLTX | PRESS-RELEASE | bullish | 7/10 | MoonLake announced positive Week 52 Phase 3 VELA data for sonelokimab in hidradenitis suppurativa, showing 67.2% HiSCR75 | Jun 21, 2026 |
| CYRX | INST-CLUSTER | mixed | 4/10 | Institutional activity in CYRX during 2026-Q1 was mixed: 7 buyers accumulated $5.7M in new positions (led by First Eagle | Jun 21, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 140,860 shares to 27 new non-executive employees under | Jun 19, 2026 |
| CAMP | PRESS-RELEASE | neutral | 2/10 | CAMP4 Therapeutics granted inducement stock options for 39,000 shares to three new hires at $3.96 per share, a routine c | Jun 19, 2026 |
| EPRX | PRESS-RELEASE | neutral | 4/10 | Eupraxia Pharmaceuticals reported Q1 2026 EPS of -$0.23, beating consensus estimates of -$0.26 by 9.8%. The filing cover | Jun 19, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Two insiders at Castle Biosciences sold a combined $189K in open-market transactions over two days. The CEO's sale was s | Jun 19, 2026 |
| CUE | S-3 | neutral | 4/10 | Cue Biopharma filed an S-3 registration statement to register 551,724 shares of common stock for resale by Ascendant Hea | Jun 18, 2026 |
| VREOF | 8-K | bullish | 6/10 | Vireo Growth Inc. (VREOF) entered into a definitive arrangement agreement to acquire all outstanding common shares of C2 | Jun 18, 2026 |
| AGIO | 8-K | neutral | 3/10 | Agios Pharmaceuticals held its 2026 Annual Meeting on June 18, 2026. Stockholders re-elected three Class I directors, ap | Jun 18, 2026 |
| VTRS | 8-K | neutral | 3/10 | Viatris completed a €650M public offering of 4.250% Senior Notes due 2033, with proceeds used to refinance its $1.675B 3 | Jun 18, 2026 |
| TWST | S-3ASR | neutral | 3/10 | Twist Bioscience filed an automatic shelf registration (S-3ASR) including a base prospectus for various securities and a | Jun 18, 2026 |
| IRON | 144 | neutral | 4/10 | Director John Quisel filed a Form 144 notice of intent to sell 34,000 shares of Disc Medicine (IRON), valued at approxim | Jun 18, 2026 |
| PTGX | 8-K | neutral | 3/10 | Protagonist Therapeutics held its 2026 Annual Meeting on June 17, 2026, where stockholders approved the new 2026 Equity | Jun 18, 2026 |
| IOVA | S-3ASR | neutral | 5/10 | Iovance Biotherapeutics filed an S-3ASR shelf registration, enabling it to offer and sell up to $89.7 million in common | Jun 18, 2026 |
| SNOA | 424B5 | bearish | 6/10 | Sonoma Pharmaceuticals filed a 424B5 prospectus supplement to increase its at-the-market (ATM) offering capacity from $2 | Jun 18, 2026 |
| SLBT | 20-F | neutral | 4/10 | SL Science Holding Limited (SLBT) filed its Form 20-F disclosing the completion of its business combination with SPAC Ho | Jun 18, 2026 |
| SNOA | 8-K | bearish | 6/10 | Sonoma Pharmaceuticals filed an 8-K to update the maximum offering amount under its existing at-the-market (ATM) equity | Jun 18, 2026 |
| GRI | 8-K | bullish | 6/10 | GRI Bio, Inc. announced that the FDA has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of Idiopath | Jun 18, 2026 |
| AKAN | 6-K | bearish | 8/10 | Akanda Corp. received a Nasdaq deficiency notice on June 16, 2026 for failing to meet the $2.5M minimum stockholders' eq | Jun 18, 2026 |
| ATNM | 8-K | bearish | 6/10 | Actinium Pharmaceuticals filed an 8-K on June 18, 2026, disclosing that it submitted a compliance plan to NYSE American | Jun 18, 2026 |
| NTHI | 8-K | bullish | 6/10 | NeOnc Technologies announced that the Department of Health, Abu Dhabi (DOH) granted Investigational New Drug (IND) statu | Jun 18, 2026 |
| VNRX | 8-K | bearish | 6/10 | VolitionRx issued 545,591 shares to Lind Global Asset Management in two tranches (May 19 and June 17, 2026) to satisfy $ | Jun 18, 2026 |
| AMRX | PREM14A | bullish | 7/10 | Amneal Pharmaceuticals is seeking shareholder approval to acquire Kashiv BioSciences, a vertically integrated biosimilar | Jun 18, 2026 |
| PCVX | CLUSTER | neutral | 3/10 | Two top C-suite executives at Vaxcyte (CEO and CFO) sold a combined ~$542K in open-market sales on June 18, 2026, follow | Jun 18, 2026 |
| ZURA | 8-K | neutral | 4/10 | Zura Bio shareholders approved an amended equity incentive plan at the June 17, 2026 Annual Meeting, increasing the shar | Jun 18, 2026 |